# Artivion, Inc.: financial statements, quarterly

AORT · NYSE · CIK 784199 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aort.md) · [Financials](/companies/aort/financials.md) · [Filings](/companies/aort/filings.md) · [Insiders](/companies/aort/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aort/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [87.9](/filings/0000784199-24-000243.md) | [93.7 d](/filings/0001628280-26-009046.md) | [97.4](/filings/0000784199-25-000074.md) | [98.0](/filings/0001628280-25-039166.md) | [95.8](/filings/0001628280-25-050502.md) | [97.3 d](/filings/0001628280-26-009046.md) | [99.0](/filings/0001628280-26-032620.md) | [113](/filings/0001628280-26-054746.md) | [113](/filings/0001628280-25-050502.md) | [116 d](/filings/0001628280-26-009046.md) | [116](/filings/0001628280-26-032620.md) | [126](/filings/0001628280-26-054746.md) |
| Cost of revenue | $m | [31.6](/filings/0000784199-24-000243.md) | [32.6 d](/filings/0001628280-26-009046.md) | [34.5](/filings/0000784199-25-000074.md) | [34.7](/filings/0001628280-25-039166.md) | [34.8](/filings/0001628280-25-050502.md) | [35.8 d](/filings/0001628280-26-009046.md) | [35.4](/filings/0001628280-26-032620.md) | [39.9](/filings/0001628280-26-054746.md) | [39.0](/filings/0001628280-25-050502.md) | [42.8 d](/filings/0001628280-26-009046.md) | [40.9](/filings/0001628280-26-032620.md) | [45.2](/filings/0001628280-26-054746.md) |
| Gross profit | $m | [56.3](/filings/0000784199-24-000243.md) | [61.1 d](/filings/0001628280-26-009046.md) | [62.9](/filings/0000784199-25-000074.md) | [63.3](/filings/0001628280-25-039166.md) | [61.0](/filings/0001628280-25-050502.md) | [61.5 d](/filings/0001628280-26-009046.md) | [63.6](/filings/0001628280-26-032620.md) | [73.1](/filings/0001628280-26-054746.md) | [74.4](/filings/0001628280-25-050502.md) | [73.1 d](/filings/0001628280-26-009046.md) | [75.4](/filings/0001628280-26-032620.md) | [80.5](/filings/0001628280-26-054746.md) |
| Research and development | $m | [6.4](/filings/0000784199-24-000243.md) | [7.6 d](/filings/0001628280-26-009046.md) | [6.9](/filings/0000784199-25-000074.md) | [7.5](/filings/0001628280-25-039166.md) | [6.6](/filings/0001628280-25-050502.md) | [7.4 d](/filings/0001628280-26-009046.md) | [6.7](/filings/0001628280-26-032620.md) | [7.1](/filings/0001628280-26-054746.md) | [8.1](/filings/0001628280-25-050502.md) | [9.1 d](/filings/0001628280-26-009046.md) | [8.8](/filings/0001628280-26-032620.md) | [9.1](/filings/0001628280-26-054746.md) |
| Selling, general and administrative | $m | [51.1](/filings/0000784199-24-000243.md) | [50.3 d](/filings/0001628280-26-009046.md) | [30.7](/filings/0000784199-25-000074.md) | [49.3](/filings/0001628280-25-039166.md) | [50.0](/filings/0001628280-25-050502.md) | [51.4 d](/filings/0001628280-26-009046.md) | [54.7](/filings/0001628280-26-032620.md) | [57.7](/filings/0001628280-26-054746.md) | [57.3](/filings/0001628280-25-050502.md) | [56.8 d](/filings/0001628280-26-009046.md) | [60.8](/filings/0001628280-26-032620.md) | [79.8](/filings/0001628280-26-054746.md) |
| Operating income | $m | [(1.2)](/filings/0000784199-24-000243.md) | [3.2 d](/filings/0001628280-26-009046.md) | [25.3](/filings/0000784199-25-000074.md) | [6.5](/filings/0001628280-25-039166.md) | [4.4](/filings/0001628280-25-050502.md) | [2.7 d](/filings/0001628280-26-009046.md) | [2.1](/filings/0001628280-26-032620.md) | [8.4](/filings/0001628280-26-054746.md) | [12.5](/filings/0001628280-25-050502.md) | [10.7 d](/filings/0001628280-26-009046.md) | [5.8](/filings/0001628280-26-032620.md) | [(8.4)](/filings/0001628280-26-054746.md) |
| Interest expense | $m | [6.6](/filings/0000784199-23-000150.md) | [6.2 d](/filings/0000784199-24-000033.md) | [7.8](/filings/0000784199-24-000172.md) | [8.3](/filings/0001628280-25-039166.md) | [8.4](/filings/0001628280-25-050502.md) | [9.7 d](/filings/0001628280-26-009046.md) | [7.7](/filings/0001628280-26-032620.md) | [7.3](/filings/0001628280-26-054746.md) | [6.1](/filings/0001628280-25-050502.md) | [5.5 d](/filings/0001628280-26-009046.md) | [5.4](/filings/0001628280-26-032620.md) | [7.3](/filings/0001628280-26-054746.md) |
| Income tax | $m | [0.4](/filings/0000784199-24-000243.md) | [3.4 d](/filings/0001628280-26-009046.md) | [5.2](/filings/0000784199-25-000074.md) | [(0.3)](/filings/0001628280-25-039166.md) | [1.0](/filings/0001628280-25-050502.md) | [(0.1) d](/filings/0001628280-26-009046.md) | [(1.8)](/filings/0001628280-26-032620.md) | [2.1](/filings/0001628280-26-054746.md) | [0.6](/filings/0001628280-25-050502.md) | [4.1 d](/filings/0001628280-26-009046.md) | [(1.1)](/filings/0001628280-26-032620.md) | [1.8](/filings/0001628280-26-054746.md) |
| Net income | $m | [(9.8)](/filings/0000784199-24-000243.md) | [(4.0) d](/filings/0001628280-26-009046.md) | [7.5](/filings/0000784199-25-000074.md) | [(2.1)](/filings/0001628280-25-039166.md) | [(2.3)](/filings/0001628280-25-050502.md) | [(16.5) d](/filings/0001628280-26-009046.md) | [(0.5)](/filings/0001628280-26-032620.md) | [1.3](/filings/0001628280-26-054746.md) | [6.5](/filings/0001628280-25-050502.md) | [2.4 d](/filings/0001628280-26-009046.md) | [1.4](/filings/0001628280-26-032620.md) | [(13.5)](/filings/0001628280-26-054746.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0000784199-24-000243.md) | not reported | [0.18](/filings/0000784199-25-000074.md) | [(0.05)](/filings/0001628280-25-039166.md) | [(0.05)](/filings/0001628280-25-050502.md) | not reported | [(0.01)](/filings/0001628280-26-032620.md) | [0.03](/filings/0001628280-26-054746.md) | [0.13](/filings/0001628280-25-050502.md) | not reported | [0.03](/filings/0001628280-26-032620.md) | [(0.28)](/filings/0001628280-26-054746.md) |
| Basic EPS | $ per share | [(0.24)](/filings/0000784199-24-000243.md) | not reported | [0.18](/filings/0000784199-25-000074.md) | [(0.05)](/filings/0001628280-25-039166.md) | [(0.05)](/filings/0001628280-25-050502.md) | not reported | [(0.01)](/filings/0001628280-26-032620.md) | [0.03](/filings/0001628280-26-054746.md) | [0.14](/filings/0001628280-25-050502.md) | not reported | [0.03](/filings/0001628280-26-032620.md) | [(0.28)](/filings/0001628280-26-054746.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [53.5](/filings/0000784199-23-000150.md) | [58.9](/filings/0000784199-25-000029.md) | [51.1](/filings/0000784199-24-000172.md) | [55.0](/filings/0000784199-24-000215.md) | [56.2](/filings/0000784199-24-000243.md) | [53.5](/filings/0001628280-26-009046.md) | [37.7](/filings/0000784199-25-000074.md) | [53.5](/filings/0001628280-25-039166.md) | [73.4](/filings/0001628280-25-050502.md) | [64.9](/filings/0001628280-26-054746.md) | [55.8](/filings/0001628280-26-032620.md) | [77.3](/filings/0001628280-26-054746.md) |
| Current assets | $m | [267](/filings/0000784199-23-000150.md) | [281](/filings/0000784199-25-000029.md) | [277](/filings/0000784199-24-000172.md) | [285](/filings/0000784199-24-000215.md) | [288](/filings/0000784199-24-000243.md) | [290](/filings/0001628280-26-009046.md) | [287](/filings/0000784199-25-000074.md) | [319](/filings/0001628280-25-039166.md) | [337](/filings/0001628280-25-050502.md) | [358](/filings/0001628280-26-054746.md) | [358](/filings/0001628280-26-032620.md) | [371](/filings/0001628280-26-054746.md) |
| Total assets | $m | [775](/filings/0000784199-23-000150.md) | [792](/filings/0000784199-25-000029.md) | [784](/filings/0000784199-24-000172.md) | [790](/filings/0000784199-24-000215.md) | [803](/filings/0000784199-24-000243.md) | [789](/filings/0001628280-26-009046.md) | [791](/filings/0000784199-25-000074.md) | [838](/filings/0001628280-25-039166.md) | [858](/filings/0001628280-25-050502.md) | [885](/filings/0001628280-26-054746.md) | [883](/filings/0001628280-26-032620.md) | [1,072](/filings/0001628280-26-054746.md) |
| Current liabilities | $m | [55.0](/filings/0000784199-23-000150.md) | [57.9](/filings/0000784199-25-000029.md) | [45.8](/filings/0000784199-24-000172.md) | [50.6](/filings/0000784199-24-000215.md) | [153](/filings/0000784199-24-000243.md) | [66.8](/filings/0001628280-26-009046.md) | [51.9](/filings/0000784199-25-000074.md) | [66.7](/filings/0001628280-25-039166.md) | [85.8](/filings/0001628280-25-050502.md) | [102](/filings/0001628280-26-054746.md) | [92.7](/filings/0001628280-26-032620.md) | [107](/filings/0001628280-26-054746.md) |
| Total liabilities | $m | [503](/filings/0000784199-23-000150.md) | [511](/filings/0000784199-25-000029.md) | [489](/filings/0000784199-24-000172.md) | [494](/filings/0000784199-24-000215.md) | [498](/filings/0000784199-24-000243.md) | [513](/filings/0001628280-26-009046.md) | [497](/filings/0000784199-25-000074.md) | [418](/filings/0001628280-25-039166.md) | [419](/filings/0001628280-25-050502.md) | [437](/filings/0001628280-26-054746.md) | [433](/filings/0001628280-26-032620.md) | [626](/filings/0001628280-26-054746.md) |
| Long-term debt | $m | [306](/filings/0000784199-23-000150.md) | [306](/filings/0000784199-25-000029.md) | [313](/filings/0000784199-24-000172.md) | [313](/filings/0000784199-24-000215.md) | [214](/filings/0000784199-24-000243.md) | [314](/filings/0001628280-26-009046.md) | [315](/filings/0000784199-25-000074.md) | [216](/filings/0001628280-25-039166.md) | [215](/filings/0001628280-25-050502.md) | [215](/filings/0001628280-26-054746.md) | [215](/filings/0001628280-26-032620.md) | [363](/filings/0001628280-26-054746.md) |
| Current portion of debt | $m | [1.6](/filings/0000784199-23-000150.md) | [1.5](/filings/0000784199-25-000029.md) | [0.3](/filings/0000784199-24-000172.md) | [0.3](/filings/0000784199-24-000215.md) | [99.7](/filings/0000784199-24-000243.md) | [0.2](/filings/0001628280-26-009046.md) | [0.1](/filings/0000784199-25-000074.md) | [0.1](/filings/0001628280-25-039166.md) | [0.0](/filings/0001628280-25-050502.md) | [0.0](/filings/0001628280-26-054746.md) | [0.0](/filings/0001628280-26-032620.md) | [0.0](/filings/0001628280-26-054746.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [272](/filings/0000784199-24-000243.md) | [282](/filings/0001628280-26-009046.md) | [295](/filings/0001628280-25-039166.md) | [295](/filings/0001628280-25-050502.md) | [305](/filings/0001628280-25-050502.md) | [276](/filings/0001628280-26-054746.md) | [294](/filings/0001628280-26-054746.md) | [420](/filings/0001628280-26-054746.md) | [439](/filings/0001628280-25-050502.md) | [448](/filings/0001628280-26-054746.md) | [450](/filings/0001628280-26-054746.md) | [446](/filings/0001628280-26-054746.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [7.2 d](/filings/0000784199-24-000243.md) | [10.8 d](/filings/0001628280-26-009046.md) | [(5.5)](/filings/0000784199-25-000074.md) | [6.1 d](/filings/0001628280-25-039166.md) | [11.5 d](/filings/0001628280-25-050502.md) | [10.1 d](/filings/0001628280-26-009046.md) | [(17.0)](/filings/0001628280-26-032620.md) | [15.0 d](/filings/0001628280-26-054746.md) | [22.3 d](/filings/0001628280-25-050502.md) | [19.6 d](/filings/0001628280-26-009046.md) | [1.2](/filings/0001628280-26-032620.md) | [(1.3) d](/filings/0001628280-26-054746.md) |
| Capital expenditure | $m | [2.1 d](/filings/0000784199-24-000243.md) | [2.7 d](/filings/0001628280-26-009046.md) | [3.6](/filings/0000784199-25-000074.md) | [2.5 d](/filings/0001628280-25-039166.md) | [3.6 d](/filings/0001628280-25-050502.md) | [1.4 d](/filings/0001628280-26-009046.md) | [3.6](/filings/0001628280-26-032620.md) | [3.3 d](/filings/0001628280-26-054746.md) | [4.6 d](/filings/0001628280-25-050502.md) | [27.5 d](/filings/0001628280-26-009046.md) | [8.0](/filings/0001628280-26-032620.md) | [10.7 d](/filings/0001628280-26-054746.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.1](/filings/0000784199-23-000150.md) | [40.4](/filings/0000784199-24-000172.md) | [40.8](/filings/0000784199-24-000215.md) | [40.9](/filings/0000784199-24-000243.md) | [47.9](/filings/0000784199-25-000074.md) | [41.7](/filings/0001628280-25-039166.md) | [41.8](/filings/0001628280-25-050502.md) | [42.2](/filings/0001628280-26-032620.md) | [45.4](/filings/0001628280-26-054746.md) | [48.8](/filings/0001628280-25-050502.md) | [49.7](/filings/0001628280-26-032620.md) | [48.5](/filings/0001628280-26-054746.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,756,221 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001628280-26-054746.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.